{"organizations": [], "uuid": "9096904d2e2ee8af841806e7b18ead7fe62d9ef0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-bristol-myers-squibb-says-cancer-d/brief-bristol-myers-squibb-says-cancer-drug-combo-reduces-death-risk-by-42-pct-idUSFWN1RT0N8", "country": "US", "domain_rank": 408, "title": "BRIEF-Bristol-Myers Squibb Says Cancer Drug Combo Reduces Death Risk By 42 Pct", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-16T16:33:00.000+03:00", "replies_count": 0, "uuid": "9096904d2e2ee8af841806e7b18ead7fe62d9ef0"}, "author": "", "url": "https://www.reuters.com/article/brief-bristol-myers-squibb-says-cancer-d/brief-bristol-myers-squibb-says-cancer-drug-combo-reduces-death-risk-by-42-pct-idUSFWN1RT0N8", "ord_in_thread": 0, "title": "BRIEF-Bristol-Myers Squibb Says Cancer Drug Combo Reduces Death Risk By 42 Pct", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters staff", "sentiment": "none"}, {"name": "squibb co", "sentiment": "none"}, {"name": "tmb", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 16, 2018 / 1:33 PM / Updated 11 minutes ago BRIEF-Bristol-Myers Squibb Says Cancer Drug Combo Reduces Death Risk By 42 Pct Reuters Staff 1 Min Read \nApril 16 (Reuters) - Bristol-Myers Squibb Co: \n* OPDIVO PLUS LOW-DOSE YERVOY COMBINATION REDUCES THE RISK OF PROGRESSION OR DEATH BY 42% VERSUS CHEMOTHERAPY IN FIRST-LINE LUNG CANCER PATIENTS WITH HIGH TUMOR MUTATIONAL BURDEN (TMB) \n* BRISTOL-MYERS SQUIBB - IN STUDY, YERVOY COMBINATION DEMONSTRATED SUPERIOR BENEFIT FOR CO-PRIMARY ENDPOINT OF PFS VERSUS CHEMOTHERAPY Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-16T16:33:00.000+03:00", "crawled": "2018-04-16T16:53:22.039+03:00", "highlightTitle": ""}